Psilocybin Is on a 60-Day Approval Clock. Here's Who Probably Won't Be in the Room.

This is today’s Substance Spotlight — a weekly deep-dive rotating through the 10 substance classes. Today: psychedelics and empathogens.

---

Janet had been trying to get into a psilocybin trial for two years. She had treatment-resistant depression — meaning she had tried four antidepressants over six years and none of them had worked, or had worked until they didn’t. She’d heard about the trials from a friend, looked them up, found one at a research university three states away, called them, and was told: income verification required; no travel reimbursement; the trial itself was free, but the preparation and integration sessions alongside it were not. She lived in rural New Mexico. She didn’t drive. She made $32,000 a year.

She is still waiting.

---

On April 24, 2026, the FDA issued what the agency calls National Priority Vouchers to three companies developing psychedelic-based therapies. The vouchers — a mechanism created by executive order just six days earlier — compress the standard FDA review timeline down to one to two months. The three recipients were Compass Pathways, whose synthetic psilocybin targets treatment-resistant depression; the Usona Institute, whose psilocybin targets major depressive disorder; and Transcend Therapeutics, whose methylone compound (a synthetic molecule engineered to behave like MDMA but avoid the regulatory concerns that led to Lykos Therapeutics’ rejection in August 2024) targets PTSD.

Compass is targeting a rolling New Drug Application submission in Q4 2026. FDA Commissioner Makary has indicated a decision could come by late summer or fall 2026. The VA just launched an MDMA-assisted therapy trial enrolling approximately 80 veterans with PTSD and alcohol use disorder.

The science on these compounds is real and promising. The question of who actually gets access when they’re approved has no good answer yet, and the field is not asking it loudly enough.

---

How we got here — and who we erased to get there

Psilocybin was first synthesized and identified by Albert Hofmann at Sandoz in 1958. MDMA was re-synthesized and introduced to psychotherapy by Alexander Shulgin in the late 1970s, and by the early 1980s, an estimated half-million doses had been administered in therapeutic settings by a small network of American and European therapists. Clinicians working in addiction found early evidence that these substances — in structured, guided therapeutic contexts — could help people examine their own patterns without the psychological defenses that usually block that kind of insight.

Then came 1970 and 1985. Under the Controlled Substances Act and the war on drugs, psilocybin was placed in Schedule I in 1970 — meaning no accepted medical use, high abuse potential, no research without a DEA Schedule I license. MDMA followed in 1985, when the DEA used emergency scheduling to place it in Schedule I despite a DEA administrative law judge’s recommendation that it be placed in Schedule III to allow therapeutic use. Bill Wilson, one of the co-founders of Alcoholics Anonymous, had written privately in the 1950s about his experiences with LSD-assisted therapy for alcoholism and its potential. By 1986, that conversation had been legally foreclosed.

The research void that followed lasted more than thirty years. The clinical evidence base that existed before 1985 was archived and largely ignored. The first modern psilocybin trials at Johns Hopkins and NYU didn’t start until 2006. The FDA approved a Phase 3 trial for MDMA-assisted PTSD therapy in 2017. More than two decades of potential clinical progress, lost.

The humans who lost the most in that pause were the ones who couldn’t wait. People with treatment-resistant PTSD who tried MDMA in unsupported settings without clinical structure. People with terminal cancer whose existential distress went unaddressed because their physicians had no tool. People with SUD for whom conventional treatment wasn’t working and no alternative existed.

---

The trials that built the evidence base — and who was in them

The studies that produced the evidence behind today’s priority vouchers have, by design, enrolled carefully selected populations. The Compass COMP360 Phase 2b trial for treatment-resistant depression excluded participants with substance use disorders — a constraint documented in the neuropsychopharmacology literature and standard in early-stage trials. The MAPS MDMA Phase 3 trials for PTSD used a therapeutic model that required multiple in-person preparatory sessions, the dosing session itself, and multiple integration sessions afterward — a protocol that researchers estimated runs approximately $8,000–$15,000 per patient at cost.

The Compass COMP360 Phase 2b trial for treatment-resistant depression excluded participants with substance use disorders — a constraint documented in the neuropsychopharmacology literature and standard in early-stage trials.

The trial populations that generated the approval-ready evidence were, by the numbers, predominantly White, college-educated, and living in metropolitan areas near a trial site. A 2026 review published in Brain and Behavior that surveyed psychedelic-assisted therapy research globally found that “current research and clinical implementation remain largely confined to high-income countries,” with access constrained by “cultural, ethical, regulatory, and resource-related challenges.” The review notes that meaningful cultural adaptation — understanding how these experiences interact with different cultural and spiritual frameworks — has barely begun.

MAPS, to their credit, have acknowledged this directly. In their April 2026 statement welcoming the federal executive order, MAPS welcomed the scientific momentum while flagging equity as a primary concern.

---

What harm reduction looks like when the therapy is still off-limits for most people

Here is the honest accounting of where we are. Psilocybin will likely receive FDA approval in late 2026 or 2027. When it does, it will be approved for treatment-resistant depression — a specific clinical indication requiring a formal diagnosis from a qualifying provider. It will be dispensed in licensed clinical settings. The therapy model, based on current evidence, requires certified therapists and multiple sessions. Insurance coverage under most commercial plans and Medicaid will require an act of will from payers who have shown they don’t extend that will to mental health parity without pressure.

For people using psilocybin outside of clinical settings — which, based on community harm reduction surveys, the majority of first-time psychedelic experiences involve — the approval of a clinical product changes little about their immediate access. What it does change is the conversation about screening, preparation, and integration: the practices that reduce the risk of adverse experiences and increase the likelihood that a psychedelic experience becomes therapeutically useful rather than destabilizing.

If you are supporting someone who is using or considering psilocybin outside of a clinical context: the harm reduction literature is clear that set and setting — the person’s psychological state and the physical environment — are the primary predictors of outcomes. This is not about endorsing use outside clinical trials. It is about acknowledging that people are making these decisions regardless, and that having access to accurate information about preparation and integration reduces harm. Organizations including MAPS and the Zendo Project have published harm reduction guides for this context.

For providers in behavioral health settings: the approval of psychedelic-assisted therapies will generate patient questions immediately. Being familiar with the clinical evidence, the certification requirements for practitioners, and the access constraints — geographic, financial, insurance — is the preparation step available now. Oregon’s state-regulated psilocybin service centers are already operating. Colorado’s program launched in 2024. Patients in your caseload may be asking about them.

---

What the FDA clock means — and who the hands point toward

When psilocybin clears FDA review, it will be a clinical milestone. The 56 years between its scheduling in 1970 and its first approval will represent one of the longest policy-induced gaps in medical history. The people who were denied access to a potentially effective therapy for five decades — because a federal agency in 1970 decided the drug had no accepted medical use — will not be named in the approval announcement.

Janet, in rural New Mexico, is still trying to find a trial site. If Compass’s psilocybin gets approved this fall, the clinical settings authorized to administer it will be in cities. The therapist certification required to deliver it will be expensive and new. Insurance will not cover it on day one.

The question worth asking right now, before the approval happens, is: what does it take to make the approval mean something for the people who need it most and are furthest from the clinical infrastructure being built for them? That question doesn’t have an FDA answer. It has a policy answer, an insurance answer, and a training-pipeline answer that the field has barely started writing.

It has a policy answer, an insurance answer, and a training-pipeline answer that the field has barely started writing.

The clock is ticking. The waiting rooms are in the wrong ZIP codes.